Abstract
In comparison with the median, the restricted mean survival time (RMST) has a specific advantage because it examines the whole survival curve (like the hazard ratio) and expresses the survival outcomes using time as unit of measurement (like medians). More importantly, the RMST captures the presence of a long-term survival plateau indicating a better prognosis. Previous experiences on the application of RMST are mostly focused on oncology.
Highlights
In comparison with the median, the restricted mean survival time (RMST) has a specific advantage because it examines the whole survival curve and expresses the survival outcomes using time as unit of measurement
Previous experiences on the application of RMST are mostly focused on oncology [1] but other fields are being investigated as well [2]
We assessed the RMST from the curves of long-term overall survival (OS) and progression-free survival (PFS) of the KEYNOTE-189 trial recently published by Gadgeel, et al There were 410 and 206 patients in the pembrolizumab and placebo groups, respectively
Summary
In comparison with the median, the restricted mean survival time (RMST) has a specific advantage because it examines the whole survival curve (like the hazard ratio) and expresses the survival outcomes using time as unit of measurement (like medians). Pembrolizumab in Non-Small Cell Lung Cancer: The Role of Restricted Mean Survival Time in Estimating The Long-Term Survival Benefit Kaplan-Meier estimate, Progression-free survival, Overall survival, Restricted mean survival time, Pembrolizuma.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call